-

Kirby McInerney LLP Reminds UiPath, Inc. Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the New York Southern District on behalf of those who acquired UiPath, Inc. (“UiPath” or the “Company”) (NYSE: PATH) securities during the period of December 1, 2023 to May 29, 2024, inclusive (“the Class Period”). Investors have until August 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[Click here to learn more about the class action]

On May 29, 2024, UiPath announced the sudden departure of CEO Robert Enslin. On the same day, UiPath announced disappointing first quarter 2025 financial results and significantly cut its full year 2025 revenue guidance by 10%, or $150 million. The Company attributed the poor results and guidance to several factors related to its failed turnaround strategy, including an inadequate execution strategy to scale the Company’s AI-powered growth products to reach their full potential. Additionally, UiPath reported that their investments in growth acceleration had fallen short of expectations. On this news, the price of UiPath shares declined by $6.23 per share, or approximately 34%, from $18.30 per share on May 29, 2024, to $12.07 per share on May 30, 2024.

The lawsuit alleges that throughout the Class Period, UiPath made materially false and misleading statements concerning the success of the Company’s turnaround strategy, which included rebranding UiPath as an AI-powered Business Automation Platform and overhauling the Company’s go-to-market sales strategy. The complaint alleges that (1) UiPath’s turnaround strategy had failed due to fruitless investments; (2) inconsistent execution plagued the Company’s overhauled go-to-market strategy; and (3) as a result, UiPath experienced significant difficulties closing and/or expanding large multiyear deals.

If you purchased or otherwise acquired UiPath securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:PATH

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos...

IBRX ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your ImmunityBio investments, you have until May 26, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERE...

PYPL DEADLINE NOTICE: PayPal Holdings, Inc. Investors Encouraged to Contact Kirby McInerney LLP By April 20, 2026

NEW YORK--(BUSINESS WIRE)--If you suffered a loss on your investment inPayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ:PYPL), contact Lauren Molinaro by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 20, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff ove...
Back to Newsroom